Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
PaperCitations, authors & open-access status
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 1,984 citations, 2014 year and closed oa status.
1,984
Citations
2014
Year
closed
OA Status